SEC Form 4 · accession 0001179110-15-007536
ABIOMED INC · ABMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M Weber
Officer — Chief Operating Officer
Period of report
May 7, 2015
Accepted (ET)
May 11, 2015 · 5:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000815094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 par value | May 7, 2015 | M | 25,678 | $13.88 | A | 162,408 | D | |
| Common Stock, $.01 par valueF5,F6 | May 7, 2015 | S | 19,584 | $69.9971 | D | 142,824 | D | |
| Common Stock, $.01 par valueF5,F7 | May 7, 2015 | S | 3,022 | $70.8091 | D | 139,802 | D | |
| Common Stock, $.01 par valueF5,F8 | May 7, 2015 | S | 1,949 | $71.8516 | D | 137,853 | D | |
| Common Stock, $.01 par valueF5,F9 | May 7, 2015 | S | 957 | $73.0029 | D | 136,896 | D | |
| Common Stock, $.01 par valueF5,F10 | May 7, 2015 | S | 166 | $73.7763 | D | 136,730 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $13.88 | May 7, 2015 | M | 25,678 | D | Apr 23, 2008 | Apr 23, 2017 | Common Stock | 25,678 | 74,322 | D |
| Stock Option (right to buy)F1,F2 | $13.80 | holding | — | — | — | May 23, 2009 | May 23, 2018 | Common Stock | 0 | 12,000 | D |
| Stock Option (right to buy)F3,F2 | $5.86 | holding | — | — | — | May 28, 2010 | May 28, 2019 | Common Stock | 0 | 51,000 | D |
| Stock Options (right to buy)F3,F2 | $5.86 | holding | — | — | — | Mar 31, 2010 | May 28, 2019 | Common Stock | 0 | 34,500 | D |
| Stock Option (right to buy)F3,F2 | $10.03 | holding | — | — | — | Jun 3, 2011 | Jun 3, 2020 | Common Stock | 0 | 50,000 | D |
| Stock Option (right to buy)F3,F2 | $22.44 | holding | — | — | — | May 22, 2013 | May 22, 2022 | Common Stock | 0 | 25,000 | D |
| Stock Option (Right to Buy)F3,F2 | $23.15 | holding | — | — | — | May 14, 2014 | May 14, 2023 | Common Stock | 0 | 23,000 | D |
| Stock Option (Right to Buy)F3,F4 | $21.55 | holding | — | — | — | May 14, 2015 | May 14, 2024 | Common Stock | 0 | 15,000 | D |
Explanation of responses
- F1Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan.
- F10This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $73.5300 and $73.9000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F2This option becomes exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- F3Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- F4These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- F5Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- F6This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $69.5000 and $70.4900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F7This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $70.5000 and $71.3800. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F8This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $71.5200 and $72.3900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F9This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $72.5300 and $73.4100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.